A detailed history of Parkman Healthcare Partners LLC transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Parkman Healthcare Partners LLC holds 924,140 shares of DAWN stock, worth $11.7 Million. This represents 1.82% of its overall portfolio holdings.

Number of Shares
924,140
Previous 908,822 1.69%
Holding current value
$11.7 Million
Previous $12.5 Million 2.79%
% of portfolio
1.82%
Previous 1.85%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.72 - $16.03 $194,844 - $245,547
15,318 Added 1.69%
924,140 $12.9 Million
Q2 2024

Aug 14, 2024

BUY
$12.03 - $17.69 $2.61 Million - $3.84 Million
217,010 Added 31.37%
908,822 $12.5 Million
Q1 2024

May 15, 2024

BUY
$13.56 - $17.46 $895,814 - $1.15 Million
66,063 Added 10.56%
691,812 $11.4 Million
Q4 2023

Feb 14, 2024

BUY
$9.68 - $15.37 $1.54 Million - $2.45 Million
159,341 Added 34.16%
625,749 $9.14 Million
Q3 2023

Nov 14, 2023

BUY
$11.22 - $14.86 $427,807 - $566,596
38,129 Added 8.9%
466,408 $5.72 Million
Q2 2023

Aug 11, 2023

BUY
$11.74 - $14.47 $329,412 - $406,013
28,059 Added 7.01%
428,279 $5.11 Million
Q1 2023

May 12, 2023

BUY
$12.75 - $23.41 $2.24 Million - $4.11 Million
175,737 Added 78.29%
400,220 $5.35 Million
Q4 2022

Feb 13, 2023

BUY
$18.77 - $22.0 $230,720 - $270,424
12,292 Added 5.79%
224,483 $4.83 Million
Q3 2022

Nov 14, 2022

BUY
$16.44 - $26.57 $1.6 Million - $2.59 Million
97,441 Added 84.92%
212,191 $4.25 Million
Q2 2022

Aug 12, 2022

BUY
$5.72 - $17.9 $656,370 - $2.05 Million
114,750 New
114,750 $2.05 Million

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $931M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Parkman Healthcare Partners LLC Portfolio

Follow Parkman Healthcare Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parkman Healthcare Partners LLC with notifications on news.